Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis

Blood Pressure ◽

10.1080/08037051.2016.1208730 ◽

2016 ◽

Vol 26 (3) ◽

pp. 139-149 ◽

Author(s):

Wenming Yuan ◽

Genyang Cheng ◽

Bin Li ◽

Yansheng Li ◽

Shan Lu ◽

...

Keyword(s):

Blood Pressure ◽

Receptor Antagonist ◽

Meta Analysis ◽

Reduce Blood Pressure ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor

Download Full-text

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

Yearbook of Cardiology ◽

10.1016/s0145-4145(10)79836-1 ◽

2010 ◽

Vol 2010 ◽

pp. 102-104

Author(s):

W.J. Elliott

Keyword(s):

Blood Pressure ◽

Receptor Antagonist ◽

Resistant Hypertension ◽

Controlled Trial ◽

Reduce Blood Pressure ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Treatment Resistant ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

10.1016/s0140-6736(09)61500-2 ◽

2009 ◽

Vol 374 (9699) ◽

pp. 1423-1431 ◽

Author(s):

Michael A Weber ◽

Henry Black ◽

George Bakris ◽

Henry Krum ◽

Stuart Linas ◽

...

Keyword(s):

Blood Pressure ◽

Receptor Antagonist ◽

Resistant Hypertension ◽

Controlled Trial ◽

Reduce Blood Pressure ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Treatment Resistant ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1184971.647074 ◽

2009 ◽

Author(s):

Mahboob Rahman

Keyword(s):

Blood Pressure ◽

Receptor Antagonist ◽

Resistant Hypertension ◽

Controlled Trial ◽

Reduce Blood Pressure ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Treatment Resistant ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1184971.746081 ◽

2009 ◽

Author(s):

David Pollock

Keyword(s):

Blood Pressure ◽

Receptor Antagonist ◽

Resistant Hypertension ◽

Controlled Trial ◽

Reduce Blood Pressure ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Treatment Resistant ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

The Effect of an Endothelin-Receptor Antagonist, Bosentan, on Blood Pressure in Patients with Essential Hypertension

New England Journal of Medicine ◽

10.1056/nejm199803193381202 ◽

1998 ◽

Vol 338 (12) ◽

pp. 784-791 ◽

Author(s):

Henry Krum ◽

Reuven J. Viskoper ◽

Yves Lacourciere ◽

Michael Budde ◽

Vincent Charlon

Keyword(s):

Blood Pressure ◽

Essential Hypertension ◽

Receptor Antagonist ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor

Download Full-text

Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan).

Circulation ◽

10.1161/01.cir.90.5.2510 ◽

1994 ◽

Vol 90 (5) ◽

pp. 2510-2518 ◽

Author(s):

J R Teerlink ◽

B M Löffler ◽

P Hess ◽

J P Maire ◽

M Clozel ◽

...

Keyword(s):

Heart Failure ◽

Blood Pressure ◽

Chronic Heart Failure ◽

Receptor Antagonist ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Acute Effects ◽

Download Full-text

A New Endothelin Receptor Antagonist, TAK-044, Inhibits Both ETA- and ETB-mediated Blood Pressure Responses in Rats.

The Japanese Journal of Pharmacology ◽

10.1016/s0021-5198(19)49983-6 ◽

1994 ◽

Vol 64 ◽

pp. 85

Author(s):

Shota Ikeda ◽

Keiji Kusumoto ◽

Toshifumi Watanabe ◽

Masahiko Fujino

Keyword(s):

Blood Pressure ◽

Receptor Antagonist ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Blood Pressure Responses

Download Full-text

Endothelin Receptor Antagonist

10.32388/54vclc ◽

2020 ◽

Author(s):

Keyword(s):

Receptor Antagonist ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor

Download Full-text

Faculty Opinions recommendation of Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13198963.14726480 ◽

2011 ◽

Author(s):

Luciana Mascia ◽

Ilaria Mastromauro

Keyword(s):

Subarachnoid Haemorrhage ◽

Receptor Antagonist ◽

Endothelin Receptor Antagonist ◽

Aneurysmal Subarachnoid Haemorrhage ◽

Endothelin Receptor ◽

Surgical Clipping ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8282963.8711064 ◽

2011 ◽

Author(s):

David Welsh

Keyword(s):

Receptor Antagonist ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Tissue Targeting ◽

Download Full-text